Switch theme
Sign up to access all valuation multiples
HealthCare Global Enterprises Ltd is an Indian company specializing in cancer care services. The company also operates fertility clinics, and multi-specialty hospitals providing cardiology, neurology, orthopedics, gastroenterology, urology, pulmonary, and critical care services. It operates under the Medical and Healthcare Services segment. The company's offerings include labs, diagnostic centers, robotic surgery, bone marrow transplantation, home health services, liver transplantation, surgical oncology, preventive oncology, and radiation oncology. The majority of the revenue is derived from the medical services offered to patients. The company derives the majority of its revenue from India.
1998
6.2K+
LTM Revenue $266M
LTM EBITDA $47.3M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
HCG Hospitals has a last 12-month revenue (LTM) of $266M and a last 12-month EBITDA of $47.3M.
In the most recent fiscal year, HCG Hospitals achieved revenue of $260M and an EBITDA of $49.5M.
HCG Hospitals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See HCG Hospitals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $266M | XXX | $260M | XXX | XXX | XXX |
| Gross Profit | $197M | XXX | $135M | XXX | XXX | XXX |
| Gross Margin | 74% | XXX | 52% | XXX | XXX | XXX |
| EBITDA | $47.3M | XXX | $49.5M | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 19% | XXX | XXX | XXX |
| EBIT | $23.3M | XXX | $20.6M | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | 8% | XXX | XXX | XXX |
| Net Profit | $3.0M | XXX | $5.2M | XXX | XXX | XXX |
| Net Margin | 1% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $89.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, HCG Hospitals's stock price is INR 542 (or $6).
HCG Hospitals has current market cap of INR 75.6B (or $886M), and EV of INR 90.5B (or $1.1B).
See HCG Hospitals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $886M | XXX | XXX | XXX | XXX | $0.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, HCG Hospitals has market cap of $886M and EV of $1.1B.
HCG Hospitals's trades at 4.2x EV/Revenue multiple, and 22.5x EV/EBITDA.
Equity research analysts estimate HCG Hospitals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
HCG Hospitals has a P/E ratio of 294.1x.
See valuation multiples for HCG Hospitals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $886M | XXX | $886M | XXX | XXX | XXX |
| EV (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV/Revenue | 4.0x | XXX | 4.2x | XXX | XXX | XXX |
| EV/EBITDA | 22.4x | XXX | 22.5x | XXX | XXX | XXX |
| EV/EBIT | 45.6x | XXX | 52.9x | XXX | XXX | XXX |
| EV/Gross Profit | 5.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 294.1x | XXX | 166.8x | XXX | XXX | XXX |
| EV/FCF | 225.8x | XXX | 85.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHCG Hospitals's last 12 month revenue growth is 15%
HCG Hospitals's revenue per employee in the last FY averaged $42K, while opex per employee averaged $19K for the same period.
HCG Hospitals's rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
HCG Hospitals's rule of X is 55% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for HCG Hospitals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | 17% | XXX | XXX | XXX |
| Rule of 40 | 34% | XXX | 34% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 55% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $42K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $19K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 44% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Athens Medical Centre | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
HCG Hospitals acquired XXX companies to date.
Last acquisition by HCG Hospitals was XXXXXXXX, XXXXX XXXXX XXXXXX . HCG Hospitals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was HCG Hospitals founded? | HCG Hospitals was founded in 1998. |
| Where is HCG Hospitals headquartered? | HCG Hospitals is headquartered in India. |
| How many employees does HCG Hospitals have? | As of today, HCG Hospitals has 6.2K+ employees. |
| Who is the CEO of HCG Hospitals? | HCG Hospitals's CEO is Mr. Meghraj Arvindrao Gore. |
| Is HCG Hospitals publicy listed? | Yes, HCG Hospitals is a public company listed on NSE. |
| What is the stock symbol of HCG Hospitals? | HCG Hospitals trades under HCG ticker. |
| When did HCG Hospitals go public? | HCG Hospitals went public in 2016. |
| Who are competitors of HCG Hospitals? | Similar companies to HCG Hospitals include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health. |
| What is the current market cap of HCG Hospitals? | HCG Hospitals's current market cap is $886M |
| What is the current revenue of HCG Hospitals? | HCG Hospitals's last 12 months revenue is $266M. |
| What is the current revenue growth of HCG Hospitals? | HCG Hospitals revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of HCG Hospitals? | Current revenue multiple of HCG Hospitals is 4.0x. |
| Is HCG Hospitals profitable? | Yes, HCG Hospitals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of HCG Hospitals? | HCG Hospitals's last 12 months EBITDA is $47.3M. |
| What is HCG Hospitals's EBITDA margin? | HCG Hospitals's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of HCG Hospitals? | Current EBITDA multiple of HCG Hospitals is 22.4x. |
| What is the current FCF of HCG Hospitals? | HCG Hospitals's last 12 months FCF is $4.7M. |
| What is HCG Hospitals's FCF margin? | HCG Hospitals's last 12 months FCF margin is 2%. |
| What is the current EV/FCF multiple of HCG Hospitals? | Current FCF multiple of HCG Hospitals is 225.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
